#Women's health
HSDD, menopause, sexual function and the peptide options indicated for them.
GLP-1 in PCOS: the fertility evidence gaps
A scientific debate in Clinical Nutrition ESPEN spotlights how much the field still does not know about semaglutide, PCOS, and fertility.
Tirzepatide weight loss outcomes in PCOS
A UK real-world study found similar 10-month tirzepatide weight loss in women with self-reported PCOS and women without PCOS.
Browse other coverage
Latest from the blog
Weight Regain After Stopping GLP-1 Drugs
A 2026 Bayesian meta-analysis maps how quickly body weight returns after stopping semaglutide or tirzepatide and what the trajectory looks like over time.
GLP-1 in PCOS: the fertility evidence gaps
A scientific debate in Clinical Nutrition ESPEN spotlights how much the field still does not know about semaglutide, PCOS, and fertility.
Tirzepatide powder: what the label says
Forum questions about reconstituting tirzepatide powder reveal a key fact: FDA-approved tirzepatide is supplied ready-to-inject, not as a lyophilized powder.
Tirzepatide vs care in early T2D at 2 years
A 2-year trial in Annals of Internal Medicine finds tirzepatide reduces HbA1c and weight more than intensified conventional care in early T2D.
Tirzepatide vs semaglutide: meta-analysis
A 2026 meta-analysis in Clinical Obesity pooled head-to-head and indirect trial data comparing tirzepatide and semaglutide for weight loss.
Is CJC-1295/ipamorelin flushing normal?
Facial flushing after CJC-1295 and ipamorelin injections is a known, documented reaction pattern for this peptide class, not an unusual one.